1 Green Flag for Moderna in 2022, and 1 Red Flag
The past two years have been incredible for Moderna (NASDAQ: MRNA) -- and its investors. Shares of the biotech company surged more than 430% in 2020. And they're heading for an increase of more than 180% this year. That's because Moderna brought a coronavirus vaccine to market and became one of the leading players in the field. The company went from zero product revenue and a net loss to billions in revenue and profit in just a few months.
So, what's ahead for this vaccine giant? Well, gains next year may not come as easily as they did over the past two years. Positive and negative factors will compete to determine which direction Moderna stock takes in 2022. I'm focused on two in particular. Let's take a look at one green flag for Moderna in the coming year -- and one red flag.
Image source: Getty Images.
Source Fool.com